IL161165A0 - Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist - Google Patents

Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Info

Publication number: IL161165A0
Authority: IL; Israel
Prior art keywords: telmisartan; same; sodium salt; crystalline sodium; angiotensin antagonist
Prior art date: 2001-10-31

Application number

IL16116502A

Other languages

English (en)

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-31

Filing date

2002-10-11

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161165(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-11 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2004-08-31 Publication of IL161165A0 publication Critical patent/IL161165A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL16116502A 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist IL161165A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10153737A DE10153737A1 (de)	2001-10-31	2001-10-31	Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2002/011394 WO2003037876A1 (de)	2001-10-31	2002-10-11	Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (1)

Publication Number	Publication Date
IL161165A0 true IL161165A0 (en)	2004-08-31

Family

ID=7704331

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16116502A IL161165A0 (en)	2001-10-31	2002-10-11	Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
IL161165A IL161165A (en)	2001-10-31	2004-03-30	Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL161165A IL161165A (en)	2001-10-31	2004-03-30	Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Country Status (34)

Country	Link
EP (1)	EP1442023B1 (uk)
JP (1)	JP5124076B2 (uk)
KR (1)	KR100929502B1 (uk)
CN (1)	CN100509789C (uk)
AR (1)	AR037148A1 (uk)
AT (1)	ATE370125T1 (uk)
AU (1)	AU2002338886B2 (uk)
BR (1)	BR0213568A (uk)
CA (1)	CA2463146C (uk)
CO (1)	CO5580785A2 (uk)
CY (1)	CY1107504T1 (uk)
DE (2)	DE10153737A1 (uk)
DK (1)	DK1442023T3 (uk)
EA (1)	EA007596B1 (uk)
EC (1)	ECSP045089A (uk)
ES (1)	ES2291505T3 (uk)
HR (1)	HRP20040372A8 (uk)
HU (1)	HUP0402391A3 (uk)
IL (2)	IL161165A0 (uk)
ME (1)	MEP43608A (uk)
MX (1)	MXPA04004013A (uk)
MY (1)	MY129741A (uk)
NO (1)	NO326465B1 (uk)
NZ (1)	NZ532716A (uk)
PE (1)	PE20030629A1 (uk)
PL (1)	PL211462B1 (uk)
PT (1)	PT1442023E (uk)
RS (1)	RS50879B (uk)
SA (1)	SA02230419B1 (uk)
SI (1)	SI1442023T1 (uk)
TW (2)	TWI333419B (uk)
UA (1)	UA82833C2 (uk)
UY (1)	UY27520A1 (uk)
WO (1)	WO2003037876A1 (uk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9029363B2 (en)	2003-04-30	2015-05-12	Boehringer Ingelheim International Gmbh	Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) *	2003-04-30	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US7692023B2 (en)	2004-02-11	2010-04-06	Teva Pharmaceutical Industries Ltd.	Candesartan cilexetil polymorphs
CN1953973A (zh) *	2004-05-05	2007-04-25	特瓦制药工业有限公司	高纯度坎地沙坦酯的制备
EP1805146A4 (en)	2004-10-18	2009-01-14	Reddys Lab Ltd Dr	PROCESS FOR THE PREPARATION OF TELMISARTAN
EP1807400A2 (en) *	2004-11-03	2007-07-18	Teva Pharmaceutical Industries, Inc.	Amorphous and polymorphic forms of telmisartan sodium
EP1908469A1 (en)	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) *	2008-07-29	2010-02-10	Sandoz AG	Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
AU2010251194B2 (en)	2009-05-20	2016-02-25	Boehringer Ingelheim Vetmedica Gmbh	Pharmaceutical oral telmisartan solution
WO2011002425A2 (en)	2009-07-02	2011-01-06	Bilgig Mahmut	Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en)	2009-07-02	2011-01-06	Mahmut Bilgic	Solubility enhancing pharmaceutical composition
EP2632438A1 (en)	2010-10-27	2013-09-04	KRKA, tovarna zdravil, d.d., Novo mesto	Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CU24354B1 (es)	2011-11-25	2018-08-06	Adverio Pharma Gmbh	Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
PT3209647T (pt)	2014-10-21	2020-09-10	Ariad Pharma Inc	Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
KR101872726B1 (ko) *	2016-07-28	2018-06-29	주식회사 씨트리	텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
HRP20240703T1 (hr)	2017-07-07	2024-08-16	Boehringer Ingelheim Vetmedica Gmbh	Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka
CN113330013B (zh) *	2019-01-10	2022-12-27	石药集团中奇制药技术（石家庄）有限公司	杂环化合物盐及其应用
TW202508455A (zh)	2023-05-24	2025-03-01	德商百靈佳殷格翰維美迪加股份有限公司	包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
CN121218995A (zh)	2023-05-24	2025-12-26	勃林格殷格翰动物保健有限公司	包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防
WO2025125409A1 (en)	2023-12-15	2025-06-19	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614519A (en) *	1991-02-06	1997-03-25	Karl Thomae Gmbh	(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) *	1991-02-06	1997-01-14	Dr. Karl Thomae Gmbh	Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) *	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US6174910B1 (en) *	1996-02-29	2001-01-16	Novartis Ag	AT1 receptor antagonist for the stimulation of apoptosis
DE19901921C2 (de) *	1999-01-19	2001-01-04	Boehringer Ingelheim Pharma	Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

2001
- 2001-10-31 DE DE10153737A patent/DE10153737A1/de not_active Ceased
2002
- 2002-10-11 DE DE50210719T patent/DE50210719D1/de not_active Expired - Lifetime
- 2002-10-11 PT PT02777305T patent/PT1442023E/pt unknown
- 2002-10-11 PL PL367477A patent/PL211462B1/pl unknown
- 2002-10-11 CN CNB028216202A patent/CN100509789C/zh not_active Expired - Fee Related
- 2002-10-11 HR HRP20040372AA patent/HRP20040372A8/hr not_active IP Right Cessation
- 2002-10-11 RS YUP-363/04A patent/RS50879B/sr unknown
- 2002-10-11 SI SI200230594T patent/SI1442023T1/sl unknown
- 2002-10-11 NZ NZ532716A patent/NZ532716A/en not_active IP Right Cessation
- 2002-10-11 ES ES02777305T patent/ES2291505T3/es not_active Expired - Lifetime
- 2002-10-11 AU AU2002338886A patent/AU2002338886B2/en not_active Ceased
- 2002-10-11 IL IL16116502A patent/IL161165A0/xx unknown
- 2002-10-11 MX MXPA04004013A patent/MXPA04004013A/es active IP Right Grant
- 2002-10-11 BR BR0213568-0A patent/BR0213568A/pt active Search and Examination
- 2002-10-11 HU HU0402391A patent/HUP0402391A3/hu not_active Application Discontinuation
- 2002-10-11 DK DK02777305T patent/DK1442023T3/da active
- 2002-10-11 CA CA2463146A patent/CA2463146C/en not_active Expired - Fee Related
- 2002-10-11 AT AT02777305T patent/ATE370125T1/de active
- 2002-10-11 EA EA200400479A patent/EA007596B1/ru not_active IP Right Cessation
- 2002-10-11 WO PCT/EP2002/011394 patent/WO2003037876A1/de not_active Ceased
- 2002-10-11 JP JP2003540158A patent/JP5124076B2/ja not_active Expired - Lifetime
- 2002-10-11 KR KR1020047006317A patent/KR100929502B1/ko not_active Expired - Fee Related
- 2002-10-11 ME MEP-436/08A patent/MEP43608A/xx unknown
- 2002-10-11 EP EP02777305A patent/EP1442023B1/de not_active Expired - Lifetime
- 2002-10-28 PE PE2002001061A patent/PE20030629A1/es not_active Application Discontinuation
- 2002-10-28 UY UY27520A patent/UY27520A1/es not_active Application Discontinuation
- 2002-10-29 TW TW091132070A patent/TWI333419B/zh not_active IP Right Cessation
- 2002-10-29 MY MYPI20024051A patent/MY129741A/en unknown
- 2002-10-29 TW TW099114822A patent/TWI341200B/zh not_active IP Right Cessation
- 2002-10-30 AR ARP020104113A patent/AR037148A1/es active IP Right Grant
- 2002-11-05 SA SA02230419A patent/SA02230419B1/ar unknown
- 2002-11-10 UA UA20040503959A patent/UA82833C2/uk unknown
2004
- 2004-03-30 IL IL161165A patent/IL161165A/en not_active IP Right Cessation
- 2004-04-27 EC EC2004005089A patent/ECSP045089A/es unknown
- 2004-04-29 NO NO20041758A patent/NO326465B1/no not_active IP Right Cessation
- 2004-05-07 CO CO04042445A patent/CO5580785A2/es not_active Application Discontinuation
2007
- 2007-10-15 CY CY20071101332T patent/CY1107504T1/el unknown

Also Published As

Publication number	Publication date
TW200300082A (en)	2003-05-16
AU2002338886B2 (en)	2008-04-17
PT1442023E (pt)	2007-09-17
PL367477A1 (en)	2005-02-21
CA2463146A1 (en)	2003-05-08
CY1107504T1 (el)	2013-03-13
NO326465B1 (no)	2008-12-08
SI1442023T1 (sl)	2007-12-31
DE50210719D1 (de)	2007-09-27
MXPA04004013A (es)	2004-06-18
HRP20040372A2 (en)	2004-10-31
CO5580785A2 (es)	2005-11-30
EP1442023B1 (de)	2007-08-15
SA02230419B1 (ar)	2007-07-31
HRPK20040372B4 (hr)	2025-09-12
MEP43608A (en)	2011-02-10
CN100509789C (zh)	2009-07-08
AR037148A1 (es)	2004-10-27
HUP0402391A3 (en)	2010-03-29
HRP20040372A8 (hr)	2025-09-12
HUP0402391A2 (hu)	2005-03-29
EP1442023A1 (de)	2004-08-04
JP2005536445A (ja)	2005-12-02
KR20050035172A (ko)	2005-04-15
JP5124076B2 (ja)	2013-01-23
CN1578772A (zh)	2005-02-09
EA007596B1 (ru)	2006-12-29
WO2003037876A1 (de)	2003-05-08
HK1073841A1 (en)	2005-10-21
DE10153737A1 (de)	2003-05-28
TWI333419B (en)	2010-11-21
CA2463146C (en)	2011-01-25
BR0213568A (pt)	2004-09-08
RS50879B (sr)	2010-08-31
ATE370125T1 (de)	2007-09-15
TWI341200B (en)	2011-05-01
UY27520A1 (es)	2003-05-30
HRPK20040372B3 (en)	2006-02-28
YU36304A (sh)	2006-08-17
UA82833C2 (uk)	2008-05-26
MY129741A (en)	2007-04-30
NZ532716A (en)	2007-06-29
KR100929502B1 (ko)	2009-12-03
TW201034664A (en)	2010-10-01
ECSP045089A (es)	2004-06-28
IL161165A (en)	2009-12-24
NO20041758L (no)	2004-04-29
DK1442023T3 (da)	2007-11-05
EA200400479A1 (ru)	2004-10-28
ES2291505T3 (es)	2008-03-01
PE20030629A1 (es)	2003-07-14
PL211462B1 (pl)	2012-05-31

Publication	Publication Date	Title
IL161165A0 (en)	2004-08-31	Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
AU2002338886A1 (en)	2003-07-10	Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
PL370481A1 (en)	2005-05-30	Salts of valsartan
EP1683784A4 (en)	2007-08-22	DIIMONIUM SALT CONNECTION AND ITS USE
PL376575A1 (pl)	2006-01-09	Podstawione związki heterocykliczne oraz sposoby wykorzystania
EP1387680A4 (en)	2010-01-13	AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
IL163549A0 (en)	2005-12-18	Topiramate salts and compositions comprising and methods of making and using the same
IL169336A0 (en)	2007-07-04	Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
HUP0401756A3 (en)	2005-06-28	Substituted benzimidazole compounds and their use
IL164698A0 (en)	2005-12-18	Attenuation of metapneumovirus
AU2003279841A8 (en)	2004-05-04	Uses of human zven antagonists
PL373163A1 (en)	2005-08-22	Salt of (s)-pantoprazole and its hydrates
GB0207411D0 (en)	2002-05-08	Azole compounds and their therapeutic use
HUP0401641A3 (en)	2007-02-28	Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
GB2387096B (en)	2005-08-24	Tomography of curved surfaces
PL1641787T3 (pl)	2007-08-31	Podstawione diketopiperazyny i ich zastosowanie jako antagonistów oksytocyny
AU2003218715A8 (en)	2003-09-22	Azepane derivatives and their use as atk1 inhibitors
IL163605A0 (en)	2005-12-18	Use of an inhibitor or antagonist against tissue factor
IL169337A0 (en)	2007-07-04	Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
GB0227906D0 (en)	2003-01-08	Compounds and their use
SG127755A1 (en)	2006-12-29	Imidazoline compounds
IL165356A0 (en)	2006-01-15	Preparation of 4-haloalkylkylnicotinamides
ZA200406552B (en)	2009-01-28	Use of an inhibitor or antagonist against tissue factor
PL363949A1 (en)	2004-11-29	Substituted benzoylcyclohexenones and their use as herbicidal agents